In the context of the COVID-19 pandemic, the availability of quality medicines is more important than ever. Unfortunately, since the start of the sanitary crisis, shortages of medicines have increased around the world, and notably of those to treat or alleviate COVID-19 symptoms or used in intensive care units (ICUs). In addition, a number of clinical trials are under way around the world, using “repurposed” authorised medicines.
The EDQM has compiled a list of substances that are used in ICUs and in clinical trials that we constantly monitor to avoid any disruption of the supply chain, thus contributing to public health needs.
The EDQM continues to ensure the delivery of reference standards to contribute to the supply of quality medicines and to respond to this public health crisis.